Insider Trading April 10, 2026 03:34 PM

NeonC Technologies President Acquires 10,000 Shares Amid Recent Fundraising and Legal Resolution

Amir F Heshmatpour adds roughly $49k of stock as company completes private placement, settles litigation and names new accounting chief

By Sofia Navarro NTHI
NeonC Technologies President Acquires 10,000 Shares Amid Recent Fundraising and Legal Resolution
NTHI

Amir F Heshmatpour, president of NeonC Technologies Holdings, Inc. (NASDAQ: NTHI), purchased 10,000 shares on April 10, 2026, paying an average of $4.895 per share for a total of $48,949. The transaction comes as the stock fell about 14% over the prior week and follows a series of corporate moves including a roughly $16 million private placement, a legal settlement of $737,920.77, the appointment of a chief accounting officer, and an upcoming Phase 1 clinical data presentation.

Key Points

  • NeonC Technologies President Amir F Heshmatpour purchased 10,000 shares on April 10, 2026 at an average of $4.895, totaling $48,949.
  • Company stock was down roughly 14% over the prior week, trading at $5.11 with a market cap of $121.89 million; InvestingPro analysis flagged the stock as appearing overvalued relative to Fair Value.
  • NeOnc Technologies completed a roughly $16 million private placement (common stock and warrants with a $9.00 exercise price), settled litigation with Fox Infused, LLC for $737,920.77, appointed David Choi as Chief Accounting Officer, and scheduled a Phase 1 trial data presentation for March 4, 2026.

Amir F Heshmatpour, president of NeonC Technologies Holdings, Inc. (NASDAQ: NTHI), bought 10,000 shares of the companys common stock on April 10, 2026. The purchases were executed at prices ranging from $4.84 to $4.95, producing an average purchase price of $4.895 and totaling $48,949.

The trade occurred while NeonC’s share price had declined nearly 14% over the preceding week, with the stock trading at $5.11 and the company showing a market capitalization of $121.89 million. According to InvestingPro analysis cited in connection with the stock, which offers additional proprietary tips for NTHI, the shares currently appear overvalued relative to their Fair Value.

Following the April 10 transaction, Heshmatpours direct ownership in NeonC Technologies stands at 3,042,000 common shares. He also holds indirect stakes through several entities: 256,120 shares via HCWG LLC, 550,000 shares through KIG LLC, and 3,714,020 shares through AFH Holdings & Advisory, LLC.


Recent corporate actions

In separate disclosures, NeOnc Technologies Holdings, Inc. announced it raised approximately $16 million in a private placement, selling shares of common stock alongside warrants. Those warrants carry an exercise price of $9.00 per share. The company also disclosed the resolution of a prior legal matter with Fox Infused, LLC, agreeing to a payment of $737,920.77 to settle disputes arising from an agreement originally made in 2022.

Additionally, NeOnc Technologies named David Choi as Chief Accounting Officer, assigning him oversight of the companys primary accounting and financial reporting functions. The company said it plans to present Phase 1 trial data on March 4, 2026; the presentation will cover findings from a clinical trial targeting treatments for central nervous system malignancies.


These filings and announcements capture a cluster of developments - insider buying, capital raising, legal settlement, leadership appointment, and a clinical data milestone - disclosed by the company in recent reports. The mix of financing and operational updates was disclosed alongside the insider purchase and the market performance noted above.

Risks

  • Stock price volatility - the article notes a near 14% decline in the stock over the prior week, which affects shareholders and market valuations (affects capital markets and investor sentiment).
  • Dilution and financing effects - the private placement and issuance of warrants with a $9.00 exercise price could affect outstanding shares and future capital structure (impacts equity holders and capital markets).
  • Legal and clinical uncertainty - although a settlement was reached for $737,920.77, and a Phase 1 presentation is scheduled, outcomes related to legal matters and clinical data remain uncertain and could influence the companies financials and operations (impacts legal exposure and biotechnology/clinical development sectors).

More from Insider Trading

Airbnb CFO Sells $491,212 in Stock as Company Completes Debt Refinance and Draws Varied Analyst Targets Apr 10, 2026 Ginkgo Bioworks director Shetty disposes of $175k in shares to cover tax on vested PSUs Apr 10, 2026 Cirrus Logic General Counsel Sells Nearly $1.6M of Stock as Company Posts Strong Q3 Results Apr 10, 2026 Dianthus CFO Sells $738,844 in DNTH Stock; Exercises Options Under Prearranged 10b5-1 Plan Apr 10, 2026 Kymera CBO Sells $500K in Stock Following Option Exercise as Analysts Weigh In Apr 10, 2026